Thiopurine methyltransferase activity in a Korean population sample of children

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 68-74

  Park Hah, Jeong Ok ^a   Klemetsdal, Bjørg ^b   Lysaa, Roy ^b   Choi, Kwang Hae ^b   Aarbakke, Jarle ^b  

^a Yeungnam University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

AGE; ARTICLE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE; SCHOOL CHILD; SEX;

EID: 0029759012     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90169-1     Document Type: Article

References (39)

1. Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, Gisholt K, et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.
2. Jones CD, Smart C, Titus A, Blyden G, Dorvil M, Nwadike N. Thiopurine methyltransferase activity in a sample population of black subjects in Florida. Clin Pharmacol Ther 1993;53:348-53.
3. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.
4. Lee EJD, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993;54:28-33.
5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
6. Tinel M, Berson A, Pessayre D, Letteron P, Cattoni MP, Horsmans Y, Larrey D. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 1991;32:729-34.
7. Chocair PR, Duley JA, Sabbaga E, Arap S, Simmonds HA, Cameron JS. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med 1993;86:359-63.
8. Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol Ther 1989;43:77-90.
9. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992;22:1055-71.
10. Klemetsdal B, Straume B, Wist E, Aarbakke J. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 1993;44:147-52.
11. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
12. Bökkcrink JPM, Stet EH, De Abreu RA, Damen FJM, Hulscher TW, Bakker MAH, et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 1993;45:1455-63.
13. Vogt MHJ, Stet EH, De Abreu RA, Bökkerink JPM, Lambooy LHJ. Trijbels FJM. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993; 1181:189-94.
14. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 1982;20:637-58.
15. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
16. Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982;222:174-81.
17. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:7:1897-902.
18. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
19. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
20. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
21. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985-9.
22. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter]. Lancet 1993;341:1151.
23. Schütz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter]. Lancet 1993;341:436.
24. Soria-Royer C, Legendre C, Mircheva J, Premel S, Beaune P, Kreis H. Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients [letter]. Lancet 1993;341:1593-4.
25. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992;85:752-6.
26. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69:577-9.
27. Klemetsdal B, Straume B, Lysaa R, Giverhaug T, Aarbakke J. Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1995;48:495-9.
28. Weinshilboum RM, Raymond FA, Pazmiño PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
29. Endrenyi L, Patel M. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot. Br J Clin Pharmacol 1991;32:159-66.
30. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
31. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-53.
32. Klemetsdal B, Flaegstad T, Aarbakke J. Is there a gender difference in red blood cell thiopurine methyltransferase activity in healthy children? Med Pediatr Oncol 1995;25:445-9.
33. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase activity in erythrocytes from neonates compared to adults. Pharmacogenetics 1995;5:281-6.
34. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child 1991; 66:462-6.
35. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23.
36. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br J Cancer 1984;49:703-7.
37. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
38. Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993;53:747-9.
39. Woodson LC, Maus TP, Reiter C, Weinshilboum RM. Rat thiopurine methyltransferase: regulation by testosterone. J Pharmacol Exp Ther 1981;218: 734-8.